| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Incyte Corporation | ZYNYZ (retifanlimab-dlwr) - (POD1UM-304) | Non-small cell lung cancer (NSCLC) | PDUFA | Data Released | Intravenous | Oncology |
| Incyte Corporation | MRGPRX2 (INCB000262) | Spontaneous urticaria (CSU) | Phase 2 | Clinical Pause | Intravenous | Immunology |
| Incyte Corporation | Pelareorep and retifanlimab (INCMGA00012) - (IRENE) | Triple-negative breast cancer | Phase 2 | Trial Completed | Intravenous | Oncology |
| Incyte Corporation | INCB99280 | High risk resectable cutaneous squamous cell carcinoma (CSCC) | Phase 2 | Trial Planned | oral | Oncology |
| Incyte Corporation | MRGPRX4 (INCB000547) | Cholestatic pruritus (CP) | Phase 2 | Trial Discontinued | Oral | Gastroenterology |
| Indivior Pharmaceuticals Inc. | INDV-2000 | Opioid Use Disorder (OUD) | Phase 2 | Ongoing | Oral | Anti-Addiction |
| Indivior Pharmaceuticals Inc. | INDV-6001 | Opioid Use Disorder (OUD) | Phase 2 | Ongoing | Oral | Anti-Addiction |
| Indivior Pharmaceuticals Inc. | AEF0117 | Cannabis-Related Disorders (CrD) | Phase 2b | Data Released | Oral | Psychiatric |